Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Profitability
This table compares Prestige Consumer Healthcare and Maravai LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prestige Consumer Healthcare | 16.90% | 12.02% | 6.41% |
| Maravai LifeSciences | -70.40% | -22.79% | -11.82% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Prestige Consumer Healthcare and Maravai LifeSciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prestige Consumer Healthcare | 0 | 4 | 3 | 0 | 2.43 |
| Maravai LifeSciences | 1 | 1 | 3 | 0 | 2.40 |
Valuation & Earnings
This table compares Prestige Consumer Healthcare and Maravai LifeSciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prestige Consumer Healthcare | $1.14 billion | 2.45 | $214.60 million | $3.78 | 15.60 |
| Maravai LifeSciences | $185.74 million | 4.02 | -$130.77 million | ($0.90) | -3.23 |
Prestige Consumer Healthcare has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
100.0% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Prestige Consumer Healthcare has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Summary
Prestige Consumer Healthcare beats Maravai LifeSciences on 10 of the 13 factors compared between the two stocks.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
